U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H11N3O4
Molecular Weight 189.1692
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARACEMIDE

SMILES

CNC(=O)ON(C(C)=O)C(=O)NC

InChI

InChIKey=JURAJLFHWXNPHG-UHFFFAOYSA-N
InChI=1S/C6H11N3O4/c1-4(10)9(5(11)7-2)13-6(12)8-3/h1-3H3,(H,7,11)(H,8,12)

HIDE SMILES / InChI
Caracemide is a nonspecific inhibitor of macromolecules affecting the synthesis of DNA, RNA, and proteins. Caracemide is an active inhibitor of ribonucleotide reductase as evidenced in the Novikoff tumor model. These inhibitory effects are concentration-dependent with 70 percent of DNA synthesis inhibited by a drug concentration of 1 mkM with a 4 h incubation. However, RNA and protein synthesis inhibition require a concentration of 50-100 mkM. DNA strand breaks were observed only at high in vivo concentrations of 100 mkM. The antineoplastic activity of caracemide was observed in the P388 murine model and in mammary (MX-I) and colon (CX-1) human tumor xenographs implanted in the subrenal capsules of athymic mice. In the MX-1 mammary tumor, a single daily injection provided greater activity than an intermittent schedule. Caracemide was inactive against murine L1210 leukemia, B16 melanoma, Lewis lung carcinoma, CD8FI mammary carcinoma and Colon 38. The toxicity on phase I studies was frequent but generally mild. Of note, significant central nervous system dysfunction manifested by lethargy, depression, and confusion occurred in some and was not predictable. In phase I studies Caracemide failed to demonstrate efficacy in patients with advanced renal cell cancer and advanced large bowel cancer.

Approval Year

PubMed

PubMed

TitleDatePubMed
Biochemical pharmacology of N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea (caracemide; NSC-253272).
1986 Aug 15
Phase I trial of caracemide using bolus and infusion schedules.
1987 Apr
Patents

Patents

Sample Use Guides

550 mg/m2/day IV as a 16 hour infusion for 5 days repeated every 21 days
Route of Administration: Intravenous
Name Type Language
CARACEMIDE
INN   MART.   USAN  
USAN   INN  
Official Name English
NSC-253272
Code English
N-ACETYL-N-(METHYLCARBAMOYLOXY)-N'-METHYLUREA
Systematic Name English
caracemide [INN]
Common Name English
CARACEMIDE [USAN]
Common Name English
CARACEMIDE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2150
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
Code System Code Type Description
PUBCHEM
54747
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY
EPA CompTox
DTXSID00231099
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY
EVMPD
SUB06083MIG
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY
NSC
253272
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY
CAS
81424-67-1
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY
USAN
T-91
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY
ChEMBL
CHEMBL9116
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY
NCI_THESAURUS
C1037
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY
INN
5319
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY
SMS_ID
100000081626
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY
MESH
C044466
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY
FDA UNII
H74F6J185A
Created by admin on Sat Dec 16 16:53:38 GMT 2023 , Edited by admin on Sat Dec 16 16:53:38 GMT 2023
PRIMARY